A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Antitumor
Activity Study of Repotrectinib in Pediatric and Young Adult Subjects
with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or
NTRK1-3 Alterations (CARE)
Phase 2 – studying effectiveness and dosage
Conditions:
Advanced solid tumors
Sponsor: Turning Point Therapeutics Inc.
trial.available_in:
БГ
Overview
Trial status: Authorised
DOR, TTR and CBR, Intracranial tumor response, Central nervous system (CNS) progression-free survival (CNS-PFS) in subjects with measurable brain metastases, PFS and OS, PK parameters, Type, incidence, severity, timing, seriousness, and relatedness of AEs and laboratory abnormalities
ORR as determined by BICR
Description
DOR, TTR and CBR, Intracranial tumor response, Central nervous system (CNS) progression-free survival (CNS-PFS) in subjects with measurable brain metastases, PFS and OS, PK parameters, Type, incidence, severity, timing, seriousness, and relatedness of AEs and laboratory abnormalities
Who can participate
Age group: 18-64 years, 0-17 years
Gender: Female, Male
Target enrollment: 20 participants
БГ